You are here: Industry Insights > Catalent

News List

Catalent closes $1.2bn acquisition of Paragon Bioservices pharmaceutical-technology
May 22, 2019
Catalent has closed an acquisition of viral vector development and gene therapy manufacturing company Paragon Bioservices for $1.2bn.
Catalent Completes Paragon Acquisition contractpharma
May 21, 2019
$1.2 billion deal for gene therapy leader is final.
Catalent achieves global ISO accreditation cphi-online
May 15, 2019
Company is one of the first CDMOs to receive award.
Catalent invests $14 million at its Eberbach, Germany softgel facility cphi-online
May 05, 2019
Expansion includes two new softgel encapsulation lines dedicated to Catalent’s proprietary Vegicaps technology.
Catalent Accelerates Formulation and Supply for MGB Biopharma Candidate contractpharma
April 28, 2019
Catalent announced the initiation of Phase II clinical trials of MGB Biopharma’s lead candidate, MGB-BP-3, an orally-dosed drug targeting the eradication of Clostridium difficile-associated diarrhea (CDAD).
Catalent to buy gene therapy manufacturer Paragon for $1.2bn pharmaceutical-technology
April 23, 2019
Catalent to buy gene therapy manufacturer Paragon for $1.2bn...
Catalent to acquire gene therapy leader Paragon Bioservices cphi-online
April 18, 2019
Catalent to acquire gene therapy leader Paragon Bioservices
Catalent pulls off $1.2B deal for gene therapy CDMO Paragon Bioservices fiercepharma
April 16, 2019
In the second major buyout of a gene therapy manufacturer in the last three weeks, Catalent snapped up Paragon Bioservices in a $1.2 billion deal.
Catalent to Acquire Paragon for $1.2B contractpharma
April 16, 2019
To provide new expertise and capabilities in fast-growing gene therapy space.
Catalent Inaugurates Second Shanghai Facility contractpharma
April 15, 2019
To optimize global and local clinical supply solutions for China.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page